Logo image of CHR-DB-B.CA

CHORUS AVIATION INC (CHR-DB-B.CA) Stock Fundamental Analysis

TSX:CHR-DB-B - Toronto Stock Exchange - CA17040TAE25 - Currency: CAD

100.16  0 (0%)

Fundamental Rating

4

CHR-DB-B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 8 industry peers in the Passenger Airlines industry. CHR-DB-B has only an average score on both its financial health and profitability. CHR-DB-B is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year CHR-DB-B was profitable.
CHR-DB-B had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CHR-DB-B reported negative net income in multiple years.
CHR-DB-B had a positive operating cash flow in each of the past 5 years.
CHR-DB-B.CA Yearly Net Income VS EBIT VS OCF VS FCFCHR-DB-B.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -16.53%, CHR-DB-B is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
CHR-DB-B has a Return On Equity of -51.90%. This is in the lower half of the industry: CHR-DB-B underperforms 77.78% of its industry peers.
CHR-DB-B has a better Return On Invested Capital (6.82%) than 77.78% of its industry peers.
CHR-DB-B had an Average Return On Invested Capital over the past 3 years of 5.30%. This is in line with the industry average of 6.00%.
The last Return On Invested Capital (6.82%) for CHR-DB-B is above the 3 year average (5.30%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -16.53%
ROE -51.9%
ROIC 6.82%
ROA(3y)-4.73%
ROA(5y)-2.72%
ROE(3y)-14.73%
ROE(5y)-8.13%
ROIC(3y)5.3%
ROIC(5y)4.78%
CHR-DB-B.CA Yearly ROA, ROE, ROICCHR-DB-B.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

Looking at the Operating Margin, with a value of 6.78%, CHR-DB-B is in line with its industry, outperforming 44.44% of the companies in the same industry.
CHR-DB-B's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 64.61%, CHR-DB-B is doing good in the industry, outperforming 77.78% of the companies in the same industry.
In the last couple of years the Gross Margin of CHR-DB-B has declined.
Industry RankSector Rank
OM 6.78%
PM (TTM) N/A
GM 64.61%
OM growth 3Y-18.7%
OM growth 5Y-14.78%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.38%
GM growth 5Y-2.24%
CHR-DB-B.CA Yearly Profit, Operating, Gross MarginsCHR-DB-B.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CHR-DB-B is destroying value.
The number of shares outstanding for CHR-DB-B has been reduced compared to 1 year ago.
The number of shares outstanding for CHR-DB-B has been reduced compared to 5 years ago.
CHR-DB-B has a better debt/assets ratio than last year.
CHR-DB-B.CA Yearly Shares OutstandingCHR-DB-B.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CHR-DB-B.CA Yearly Total Debt VS Total AssetsCHR-DB-B.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 1.79, we must say that CHR-DB-B is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.79, CHR-DB-B is doing good in the industry, outperforming 77.78% of the companies in the same industry.
The Debt to FCF ratio of CHR-DB-B is 2.43, which is a good value as it means it would take CHR-DB-B, 2.43 years of fcf income to pay off all of its debts.
CHR-DB-B's Debt to FCF ratio of 2.43 is fine compared to the rest of the industry. CHR-DB-B outperforms 77.78% of its industry peers.
CHR-DB-B has a Debt/Equity ratio of 0.55. This is a neutral value indicating CHR-DB-B is somewhat dependend on debt financing.
With a decent Debt to Equity ratio value of 0.55, CHR-DB-B is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.43
Altman-Z 1.79
ROIC/WACC0.88
WACC7.75%
CHR-DB-B.CA Yearly LT Debt VS Equity VS FCFCHR-DB-B.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

CHR-DB-B has a Current Ratio of 0.95. This is a bad value and indicates that CHR-DB-B is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.95, CHR-DB-B perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
A Quick Ratio of 0.69 indicates that CHR-DB-B may have some problems paying its short term obligations.
The Quick ratio of CHR-DB-B (0.69) is worse than 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.69
CHR-DB-B.CA Yearly Current Assets VS Current LiabilitesCHR-DB-B.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

CHR-DB-B shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 263.33%, which is quite impressive.
CHR-DB-B shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 11.95% yearly.
CHR-DB-B shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.43%.
CHR-DB-B shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.56% yearly.
EPS 1Y (TTM)263.33%
EPS 3Y43.35%
EPS 5Y11.95%
EPS Q2Q%1100%
Revenue 1Y (TTM)-16.43%
Revenue growth 3Y11.15%
Revenue growth 5Y0.56%
Sales Q2Q%-16.21%

3.2 Future

CHR-DB-B is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.78% yearly.
Based on estimates for the next years, CHR-DB-B will show a small growth in Revenue. The Revenue will grow by 0.78% on average per year.
EPS Next Y106.63%
EPS Next 2Y30.22%
EPS Next 3Y15.78%
EPS Next 5YN/A
Revenue Next Year-1.8%
Revenue Next 2Y-1.4%
Revenue Next 3Y0.78%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CHR-DB-B.CA Yearly Revenue VS EstimatesCHR-DB-B.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
CHR-DB-B.CA Yearly EPS VS EstimatesCHR-DB-B.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 91.89 indicates a quite expensive valuation of CHR-DB-B.
Compared to the rest of the industry, the Price/Earnings ratio of CHR-DB-B indicates a slightly more expensive valuation: CHR-DB-B is more expensive than 66.67% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of CHR-DB-B to the average of the S&P500 Index (27.75), we can say CHR-DB-B is valued expensively.
With a Price/Forward Earnings ratio of 44.47, CHR-DB-B can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CHR-DB-B indicates a slightly more expensive valuation: CHR-DB-B is more expensive than 66.67% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of CHR-DB-B to the average of the S&P500 Index (20.49), we can say CHR-DB-B is valued expensively.
Industry RankSector Rank
PE 91.89
Fwd PE 44.47
CHR-DB-B.CA Price Earnings VS Forward Price EarningsCHR-DB-B.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CHR-DB-B is valued a bit more expensive than 77.78% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CHR-DB-B is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 12.52
EV/EBITDA 13.94
CHR-DB-B.CA Per share dataCHR-DB-B.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CHR-DB-B's earnings are expected to grow with 15.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.86
PEG (5Y)7.69
EPS Next 2Y30.22%
EPS Next 3Y15.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CHR-DB-B!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHORUS AVIATION INC

TSX:CHR-DB-B (4/16/2025, 7:00:00 PM)

100.16

0 (0%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryPassenger Airlines
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners1.95%
Inst Owner ChangeN/A
Ins Owners1.18%
Ins Owner ChangeN/A
Market Cap2.66B
Analysts78.18
Price Target133.9 (33.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.98
Dividend Growth(5Y)21.58%
DP-10.08%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)116.73%
Min EPS beat(2)25.51%
Max EPS beat(2)207.96%
EPS beat(4)3
Avg EPS beat(4)41.76%
Min EPS beat(4)-80.2%
Max EPS beat(4)207.96%
EPS beat(8)3
Avg EPS beat(8)6.63%
EPS beat(12)4
Avg EPS beat(12)0%
EPS beat(16)7
Avg EPS beat(16)1.16%
Revenue beat(2)0
Avg Revenue beat(2)-5.87%
Min Revenue beat(2)-7.96%
Max Revenue beat(2)-3.78%
Revenue beat(4)1
Avg Revenue beat(4)-4.04%
Min Revenue beat(4)-10.27%
Max Revenue beat(4)5.86%
Revenue beat(8)4
Avg Revenue beat(8)-1.07%
Revenue beat(12)6
Avg Revenue beat(12)0.32%
Revenue beat(16)9
Avg Revenue beat(16)5.8%
PT rev (1m)-3.99%
PT rev (3m)0.01%
EPS NQ rev (1m)-3.66%
EPS NQ rev (3m)676.19%
EPS NY rev (1m)0%
EPS NY rev (3m)636.31%
Revenue NQ rev (1m)-0.33%
Revenue NQ rev (3m)1.03%
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)-0.42%
Valuation
Industry RankSector Rank
PE 91.89
Fwd PE 44.47
P/S 1.89
P/FCF 12.52
P/OCF 10.02
P/B 5.19
P/tB 5.28
EV/EBITDA 13.94
EPS(TTM)1.09
EY1.09%
EPS(NY)2.25
Fwd EY2.25%
FCF(TTM)8
FCFY7.99%
OCF(TTM)9.99
OCFY9.98%
SpS52.98
BVpS19.3
TBVpS18.97
PEG (NY)0.86
PEG (5Y)7.69
Profitability
Industry RankSector Rank
ROA -16.53%
ROE -51.9%
ROCE 9.2%
ROIC 6.82%
ROICexc 8.69%
ROICexgc 8.78%
OM 6.78%
PM (TTM) N/A
GM 64.61%
FCFM 15.1%
ROA(3y)-4.73%
ROA(5y)-2.72%
ROE(3y)-14.73%
ROE(5y)-8.13%
ROIC(3y)5.3%
ROIC(5y)4.78%
ROICexc(3y)5.99%
ROICexc(5y)5.28%
ROICexgc(3y)6.05%
ROICexgc(5y)5.32%
ROCE(3y)7.14%
ROCE(5y)6.44%
ROICexcg growth 3Y33.52%
ROICexcg growth 5Y7.31%
ROICexc growth 3Y33.18%
ROICexc growth 5Y7.15%
OM growth 3Y-18.7%
OM growth 5Y-14.78%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.38%
GM growth 5Y-2.24%
F-Score6
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.43
Debt/EBITDA 1.34
Cap/Depr 45.44%
Cap/Sales 3.76%
Interest Coverage 1.21
Cash Conversion 125.19%
Profit Quality N/A
Current Ratio 0.95
Quick Ratio 0.69
Altman-Z 1.79
F-Score6
WACC7.75%
ROIC/WACC0.88
Cap/Depr(3y)31.44%
Cap/Depr(5y)62.49%
Cap/Sales(3y)3.58%
Cap/Sales(5y)12.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)263.33%
EPS 3Y43.35%
EPS 5Y11.95%
EPS Q2Q%1100%
EPS Next Y106.63%
EPS Next 2Y30.22%
EPS Next 3Y15.78%
EPS Next 5YN/A
Revenue 1Y (TTM)-16.43%
Revenue growth 3Y11.15%
Revenue growth 5Y0.56%
Sales Q2Q%-16.21%
Revenue Next Year-1.8%
Revenue Next 2Y-1.4%
Revenue Next 3Y0.78%
Revenue Next 5YN/A
EBIT growth 1Y-63.67%
EBIT growth 3Y-9.64%
EBIT growth 5Y-14.31%
EBIT Next Year78.26%
EBIT Next 3Y15.88%
EBIT Next 5YN/A
FCF growth 1Y-17.3%
FCF growth 3Y24.37%
FCF growth 5YN/A
OCF growth 1Y-11.57%
OCF growth 3Y12.73%
OCF growth 5Y0.25%